Biomarin Pharmaceutical Inc BMRN:NASDAQ ; Last | PM EDT. quote price arrow down (%) ; Volume. , ; 52 week range. - BioMarin Pharmaceutical Stock Forecast ; Strong buy ratings: 17, 17 ; Buy ratings: 0, 0 ; Hold ratings: 9, 10 ; Sell ratings: 0, 0. Biomarin Pharmaceutical Inc is listed and trades on the NASDAQ stock exchange. Is Biomarin Pharmaceutical Inc a Good Stock to Buy? Determining whether Biomarin. Analyst Ratings. The average analyst rating for BMRN stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to. So, Which Is the Better Investment, Biomarin Pharmaceutical Inc or Biogen Inc Stock? Overall, Biomarin Pharmaceutical Inc stock has a Growth Score of
Is Biomarin Pharmaceutical Stock Undervalued? The current Biomarin Pharmaceutical [BMRN] share price is $ The Score for BMRN is 64, which is 28% above its. Is BioMarin Pharmaceutical a good stock to buy? BioMarin Pharmaceutical has a PEG Ratio of PEG Ratios above 1 indicate that a company could be. Is Now A Good Time To Buy BioMarin Stock? Jim Halley | Jan 22, Shares in this biotech company are down considerably from where they were this summer. How To Invest In Biomarin · Details · Is Biomarin Stock a good investment? Investors use various methods to calculate intrinsic value and buy a stock when its. BioMarin Pharmaceutical Stock vs. The Competition ; Consensus Rating Score. ; Consensus Rating, Moderate Buy, Moderate Buy ; Predicted Upside, %. Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Biomarin Pharmaceutical is 'Strong Sell'. BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is , and is based on 12 buy ratings. View BioMarin Pharmaceutical Inc. BMRN stock quote prices, financial Buy on BioMarin Pharmaceutical (BMRN) by TipRanks Jun 08 am ET Analysts. Assess the Biomarin Pharma stock price estimates. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst Month.
BMRN Earnings Consensus. Consensus. Strong Buy. Based on 27 analysts offering recommendations for 'BMRN'. Zacks' proprietary data indicates that BioMarin Pharmaceutical Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BMRN. Biomarin Pharmaceutical stock has received a consensus rating of buy. The average rating score is and is based on 48 buy ratings, 22 hold ratings, and 1 sell. Does BioMarin have a direct stock purchase plan? BioMarin does not currently have a direct stock purchase plan. Who is BioMarin's Transfer Agent? Click here. BioMarin Pharmaceutical currently has an average brokerage recommendation (ABR) of on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on. A high-level overview of BioMarin Pharmaceutical Inc. (BMRN) stock. Stay Strong Buy Stocks - Short Squeeze · Top REITs · ETF Screener Collapse menu. All. The company reported $ earnings per share for the quarter, beating the consensus estimate of $ by $ Is BioMarin Pharmaceutical overvalued? BioMarin Pharmaceutical started at buy with $ stock price target at UBS Biotech and Pharma Why Biotech Stocks Keep Falling on Good News. Jul. BioMarin's One-Year Data on Its Hemophilia Gene-Therapy Looked Good. BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says.
technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further. Biomarin Pharmaceutical Stock Forecast FAQ Is Biomarin Pharmaceutical Stock a good buy in , according to Wall Street analysts? The consensus among 10 Wall. BioMarin Pharmaceutical Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: BMRN | Nasdaq. What analysts recommend for BMRN stock, on a scale from 1(buy) to 5(sell). Buy. Strong Buy 34%. The average one-year price target for BioMarin Pharmaceutical Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price.